glp 1 agonist liver disease GLP-1_receptor_som_behandling_af_steatotisk_leversygdom Frontiers | Glucagon-like peptide-1 and

10.1038/s41574-019-0156-z 9 CaniP

354 GLP-1RAs and musculoskeletal health GLP-1RAs and bone The quality of bone depends on bone metabolism, and the main factors affecting bone metabolism include osteoclasts, osteoblasts, and calcitonin

Several studies have relatively short follow-up periods and limited sample sizes, which may constrain the evaluation of long-term efficacy and durability

GLP-1 analogues are all injectable therapies, which may be a drawback for some patients, although oral semaglutide is in development and was recently approved by the US Food and Drug Administration

The present study aims to investigate comparative dementia risk with initiators of GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors in people with type 2 diabetes aged 60 years, using real-world observational data from primary care practice records in the UK